Archives

by in
Entry Author Date Location
East Coast Biotech Roundup: Hemophilia, Levin, Vertex, Semma & More 03/27/15 Boston
Epizyme Buys Back Control of Cancer Drug From Eisai For up to $110M 03/12/15 Boston
Ex-Alnylam Exec to Steer Warp Drive Bio; Verdine Shifts Roles 03/04/15 Boston
Bellicum CEO Reflects on Rise From Baylor to Houston Biotech Darling 02/26/15 Texas
Flexus Speeds From Inception to $1.25B Bristol Buyout In Less Than Two Years 02/23/15 San Francisco
East Coast Biotech Roundup: Vertex, Syndax, Build-to-Buy Deals & More 02/20/15 Boston
West Coast Biotech Roundup: Zymeworks, Lee Hood, Sue Biggins, Nektar 01/22/15 Seattle
J.P. Morgan 2015: Notes, Thoughts, And Conversations From the Vortex 01/16/15 National
East Coast Biotech Roundup: Foundation, Biogen, Moderna, & Lots More 01/16/15 Boston
West Coast Biotech Roundup: Gilead/AbbVie, Juno, Auspex, Bina & More 12/23/14 San Francisco
East Coast Biotech Roundup: Yumanity, Padlock, CAR-T Fever, & More 12/19/14 Boston
Houston’s Bellicum Pharma Rides T-Cell Therapy Wave to $140M IPO 12/18/14 Texas
ASH Roundup: Immunotherapy Stars, Gene Therapy Leaps Ahead 12/11/14 San Francisco
With New Data, Agios Plots Quick Turn into Key Late-Stage Trials 12/07/14 Boston
Prescription Drug Pricing: The Fine Line Between Value and Greed 12/02/14 Boston
Déjà Vu for Agios as Second Drug Shines in Small Blood Cancer Study 11/18/14 Boston
Juno, Less Than a Year Old, Lines up IPO to Fund Cancer Work 11/17/14 Seattle
What Early Looks From ASH Tell Us About Cancer Immunotherapy 11/07/14 National
NimbleGen Cofounder Opens Invenra, A “Cell-Free” Antibody Shop 11/05/14 Wisconsin
Opsona, And Pharma Backers, Await Day of Reckoning for Kidney Drug 10/29/14 National
Bio Venture Specialists Advent Raise $235M For European, U.S. Deals 10/28/14 National
East Coast Biotech Roundup: PureTech, Celgene, Unum, Biogen & More 10/24/14 Boston
West Coast Biotech Roundup: Genentech, Sutro, Amgen, Regulus & More 10/23/14 San Francisco
Try Then Buy? Sutro Deal Could Be Celgene’s Biggest Antibody Bet Yet 10/23/14 New York
Atara Bio Pays the Price for Delayed IPO, Sinks in Debut 10/16/14 San Francisco
With $24M and Pharma Backing, Ex Epizyme Prez Aims to “Raze” Tumors 10/14/14 Boston
Six Takeaways from Boston’s Life Science Disruptors 10/13/14 Boston
What Seattle Needs (Part 3): Working Together to Revitalize Biotech 10/08/14 Seattle
Raleigh-Durham Roundup: Tengion, IBM, Velocity, & More 09/29/14 Raleigh Durham
Ex-Elan Trio Grabs Their Former Employer’s Kinase Inhibitor Program 09/29/14 San Francisco
Page 1 of 9 next page »